Total Access Medical - Direct Primary Care Blog

Four COVID-19 Vaccines Compared

Posted by Total Access Medical on Feb 01, 2021

Screen Shot 2021-02-01 at 10.27.18 AMTwo vaccines have been approved for use in the United States. A third and fourth are coming soon. Here’s a closer look at them and what it might mean for you.

Vaccine Developer: Pfizer Moderna AstraZeneca Johnson & Johnson 
How it works Messenger RNA Messenger RNA Inactivated cold virus Modified cold virus
When approved / expected approval December 11th December 18th

Has not submitted application for emergency use authorization in U.S.

Plans to submit application for emergency use authorization in U.S. in February.

What percentage of people did it protect from getting infected in clinical studies?

95% 94.1% 70% 66%
How many shots do you need?

Two doses, 3 weeks apart

Two doses, 4 weeks apart

Two doses, a month apart

One dose 
What are the side effects?

Fatigue, headache, chills, muscle pain, especially after the second dose

Fever, muscle aches, headaches, lasting a few days. Effects worse after second dose Injection site pain, fever, muscle aches, headache  Not yet available 
How many doses will be available, and when?

50 million, starting Dec. 18; 1.3 billion in 2021

20 million, starting Dec. 21; 80 million for U.S. in 2021

3 billion planned for 2021

Not yet available 
Who is it recommended for? People 16 and older People 18 and older Not yet available Not yet available 
Is there anyone who shouldn't get the vaccine?

People with a history of serious allergic reactions, anyone with a history of allergic reactions to vaccine ingredients including polyethylene glycol, and anyone with a history of allergic reactions to polysorbate.

People with a history of serious allergic reactions, anyone with a history of allergic reactions to vaccine ingredients including polyethylene glycol, and anyone with a history of allergic reactions to polysorbate.

Not yet available  Not yet available 
Any negative side effects?

0 cases of anaphylaxis in people who received the vaccine, mostly women.

Four cases of Bell's palsy, a type of temporary facial paralysis, reported in people who received the vaccine. This is not more than would be expected in the general population.

21 cases of anaphylaxis in people who received the vaccine, all in women.

Four cases of Bell's palsy reported in the clinical trials including 3 in the vaccine group, and 1 in the placebo group. This is not more than would be expected in the general population.

Four total serious side effects, including two cases of transverse myelitis.

One person went to the hospital for fever associated with the vaccine. Four other serious cases were not related to the vaccine.

What about people with lowered immune function?

Ok for people whose immune function is lowered by HIV or immunosuppressing drugs if they have no other reasons to avoid it. There is limited safety data in this group.

Ok for people whose immune function is lowered by HIV or immunosuppressing drugs if they have no other reasons to avoid it. There is limited safety data in this group.

Not yet available  Not yet available 
What about people with autoimmune diseases?

No data are available on the safety or effectiveness of mRNA vaccines in people with autoimmune disease. People with autoimmune conditions may still get the shots if they have no other reasons to avoid vaccination.

No data are available on the safety or effectiveness of mRNA vaccines in people with autoimmune disease. People with autoimmune conditions may still get the shots if they have no other reasons to avoid vaccination.

Not yet available  Not yet available 
Is the vaccine safe for people with a history of

Guillain- Barre Syndrome (GBS)?

To date, no cases of GBS have been seen in people vaccinated for COVID-19. The CDC says a history of GBS is not a reason to avoid vaccination.

To date, no cases of GBS have been seen in people vaccinated for COVID-19. The CDC says a history of GBS is not a reason to avoid vaccination.

Not yet available  Not yet available 

New Call-to-action